Sartorius AG
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions. The company offers a comprehensive portfolio of products and services that are essential for life science research and biopharmaceutical manufacturing. Its offerings include sophisticated biosensors, detection systems, live-cell…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
1D
-0.3%
1W
+3.2%
1M
+7.7%
6M
+9.3%
YTD
+5.6%
1Y
+14.2%
2Y
+14.2%
5Y
-50.4%
10Y
+230.6%
Next earnings date
22/10/2026 (in 5 days)
Volatility around earnings
~75% stronger price swings than usual
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
P/E
92.23
P/B
6.38
EV/EBITDA
18.9
RETURN ON EQUITY
1.5%
NET MARGIN
4.5%
DEBT/EQUITY
1.44
DIVIDEND YIELD
0.3%
AS OF
30/06/2026
FREE FLOAT
53.9%
FLOAT SHARES
32,967,394
AVG. DAILY VOLUME (30D)
101,838
Sartorius AG is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Germany.
The CEO is Michael Grosse, the company employs around 14,279 people.
The IPO was on 28/04/1999; the stock trades on XETRA under the ticker SRT3.DE.
The next earnings date is 22/10/2026.
Around past earnings, price swings were roughly 75% stronger than usual.
Yes. The last dividend was €0.74 per share, ex-date 27/03/2026, paid on 31/03/2026.
The dividend yield is 0.3% (as of 30/06/2026).
Comparable stocks include Anbio Biotechnology, Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International and Cooper Companies.
Clicking "Analyze stock" lets five strategies assess Sartorius against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.